GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

Last update: 21 Aug, 7:06PM

75.13

0.38 (0.51%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Mixed
Drug Manufacturers - General (Global) Bullish Mixed
Stock Gilead Sciences, Inc. Bullish Bearish

Stockmoo Score

0.3

Similar Stocks

Stock Market Cap DY P/E P/B
GILD 94 B 4.07% 91.62 5.38
AMGN 172 B 2.77% 55.27 29.05
AZN 272 B 1.70% 42.53 6.52
SNY 131 B 7.78% 28.79 1.94
GRFS 6 B - 29.50 0.980
BIIB 29 B - 25.45 1.85

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
52 Weeks Range
62.07 (-17%) — 87.87 (16%)
Price Target Range
70.00 (-6%) — 93.00 (23%)
High 93.00 (Raymond James, 23.79%) Buy
Median 81.50 (8.48%)
Low 70.00 (Cantor Fitzgerald, -6.83%) Hold
Average 80.83 (7.59%)
Total 2 Buy, 4 Hold
Avg. Price @ Call 72.81
Firm Date Target Price Call Price @ Call
RBC Capital 04 Sep 2024 74.00 (-1.50%) Hold 79.13
09 Aug 2024 72.00 (-4.17%) Hold 73.66
Truist Securities 15 Aug 2024 83.00 (10.48%) Hold 74.34
BMO Capital 09 Aug 2024 85.00 (13.14%) Buy 73.66
Cantor Fitzgerald 09 Aug 2024 70.00 (-6.83%) Hold 73.66
22 Jul 2024 70.00 (-6.83%) Hold 72.41
Raymond James 08 Jul 2024 93.00 (23.79%) Buy 67.55
Baird 20 Jun 2024 80.00 (6.48%) Hold 68.49
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
MERCIER JOHANNA - 78.56 -9,513 -747,341
Aggregate Net Quantity -9,513
Aggregate Net Value ($) -747,341
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 78.56
Name Holder Date Type Quantity Price Value ($)
MERCIER JOHANNA Officer 28 Aug 2024 Automatic sell (-) 9,513 78.56 747,341
Date Type Details
05 Sep 2024 Announcement Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
21 Aug 2024 Announcement Gilead Sciences to Present at Upcoming Investor Conferences
16 Aug 2024 CNBC Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
14 Aug 2024 Announcement Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
08 Aug 2024 Announcement Gilead Sciences Announces Second Quarter 2024 Financial Results
25 Jul 2024 Announcement Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
25 Jul 2024 Announcement Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
24 Jul 2024 Announcement Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
22 Jul 2024 Announcement Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
17 Jul 2024 Announcement Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
16 Jul 2024 Announcement Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
20 Jun 2024 Announcement Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
20 Jun 2024 CNBC Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
14 Jun 2024 Announcement New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
Show more
TTM Dividend Yield 4.07%
5Y Average Dividend Yield 3.91%
Expected Next Dividend Payment Dec 2024
Ex Date Announcement Date Payment Date Details
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 Cash
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 Cash
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 Cash
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 Cash
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 Cash
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 Cash
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 Cash
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 Cash
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 Cash
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 Cash
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 Cash
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 Cash
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 Cash
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 Cash
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 Cash
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 Cash
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 Cash
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 Cash
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 Cash
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 Cash
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 Cash
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 Cash
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 Cash
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 Cash
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 Cash
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 Cash
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 Cash
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 Cash
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 Cash
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 Cash
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 Cash
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 Cash
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 Cash
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 Cash
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 Cash
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 Cash
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 Cash
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 2.31 3 3.08
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria